| 000 | 01649 a2200493 4500 | ||
|---|---|---|---|
| 005 | 20250517102811.0 | ||
| 264 | 0 | _c20170216 | |
| 008 | 201702s 0 0 eng d | ||
| 022 | _a1768-3254 | ||
| 024 | 7 |
_a10.1016/j.ejmech.2016.06.021 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aHou, Wen | |
| 245 | 0 | 0 |
_aNovel securinine derivatives as topoisomerase I based antitumor agents. _h[electronic resource] |
| 260 |
_bEuropean journal of medicinal chemistry _cOct 2016 |
||
| 300 |
_a149-163 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 |
_aAntineoplastic Agents _xchemistry |
| 650 | 0 | 4 |
_aAzepines _xchemistry |
| 650 | 0 | 4 | _aCell Line, Tumor |
| 650 | 0 | 4 |
_aCell Proliferation _xdrug effects |
| 650 | 0 | 4 |
_aDNA Cleavage _xdrug effects |
| 650 | 0 | 4 |
_aDNA Topoisomerases, Type I _xchemistry |
| 650 | 0 | 4 | _aDrug Design |
| 650 | 0 | 4 |
_aHeterocyclic Compounds, Bridged-Ring _xchemistry |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aLactones _xchemistry |
| 650 | 0 | 4 | _aModels, Molecular |
| 650 | 0 | 4 |
_aPiperidines _xchemistry |
| 650 | 0 | 4 | _aProtein Conformation |
| 650 | 0 | 4 | _aStructure-Activity Relationship |
| 650 | 0 | 4 |
_aTopoisomerase I Inhibitors _xchemistry |
| 700 | 1 | _aWang, Zhen-Ya | |
| 700 | 1 | _aPeng, Cheng-Kang | |
| 700 | 1 | _aLin, Jing | |
| 700 | 1 | _aLiu, Xin | |
| 700 | 1 | _aChang, Yi-Qun | |
| 700 | 1 | _aXu, Jun | |
| 700 | 1 | _aJiang, Ren-Wang | |
| 700 | 1 | _aLin, Hui | |
| 700 | 1 | _aSun, Ping-Hua | |
| 700 | 1 | _aChen, Wei-Min | |
| 773 | 0 |
_tEuropean journal of medicinal chemistry _gvol. 122 _gp. 149-163 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/j.ejmech.2016.06.021 _zAvailable from publisher's website |
| 999 |
_c26161392 _d26161392 |
||